Themis Medicare Limited has informed the Exchange about Investor Presentation
TML/BSE/NSE/2025-26/17
1st August, 2025
The Manager Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code – 530199
The Manager – Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Symbol: THEMISMED
Dear Sir/Madam,
Subject: Investor Presentation
In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), we submit herewith the Investors’ Presentation of the Company, with respect to Business Overview of Themis Medicare Limited (‘the Company’).
Further, a copy of the same is also available on the website of the Company, viz., https://www.themismedicare.com
Kindly take the same on record and acknowledge receipt of the same.
Thanking you,
Yours faithfully,
For THEMIS MEDICARE LIMITED
Pradeep Chandan Director – Legal, Compliance & Company Secretary
Themis Medicare Limited Corporate Office: 11/12 Udyog Nagar, S V Road, Goregaon (W), Mumbai – 400 104, India *Tel.: 91-22-67607080*Fax: 91-22-67607070/ 28746621 Regd. Office: Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi-Gujarat CIN No.: L24110GJ1969PLC001590 *Tel/ Fax No.: Regd. Off.: 0260-2431447/ 2430219 *E-mail: themis@themismedicare.com*Website: www.themismedicare.com
In every possibility lies an innate, latent power to change lives
Themis Medicare Ltd.
Result Update Presentation Q1 FY26
Disclaimer
This presentation has been prepared by Themis Medicare Limited (the “Company” or “Themis” or “TML”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.
This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.
Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.
2
Table of Contents
Consolidated Financial Highlights
Company Overview
Way Ahead
3
Management Comment
Commenting on the result, Dr. Sachin Patel, Managing Director & CEO, said:
“The Company’s performance in this quarter was significantly impacted due to disruption in a high margin major line of Business on account of substandard imitation in the market. In this regard, the Company has taken the matter strongly with regulators who are currently investigating the matter. Despite this, there are promising trends across several segments. The API business showed strong recovery with 77% year-on-year growth, indicating early signs of stability and better visibility for the remainder of the year. Furthermore, the Institution business also grew in Q1, giving an optimistic outlook for the coming quarters.
The Pharma business achieved 19% year-on-year growth on the back of targeted brands, aided by improved PCPM productivity. We will continue to drive this momentum with strategic rate contracts and penetrating further into corporate hospitals. In the exports business, performance was level as we had order delays which are now anticipated to be achieved in Q2.
Moving forward, we are emphasizing cost rationalization, optimizing field force productivity, enhanced working capital management, and selective investments in high-margin brands. Our R&D pipeline continues to be robust, and we will keep directing our efforts into creating differentiated products in critical therapeutic categories.
Consolidated revenue for the quarter was at ₹98 crore; muted performance in the formulations business impacted profitability. Consolidated TTM EPS is Rs. 2.60. We remain optimistic for a much better bounce back in the subsequent quarters as all our strategic efforts pick up pace."
4
Consolidated Financial Highlights
Consolidated Quarterly Financial Highlights
Revenue (Rs. Cr.)* 123.0
117.0
EBITDA (Rs. Cr.)** / Margin (%)
93.8
97.6
71.7
23.7%
29.2
14.6%
17.1
9.1%
8.5
-8.1%
-10.3%
Q1 FY25
Q2 FY25
Q3 FY25
Q4 FY25
Q1 FY26
Q1 FY25
Q2 FY25
Q3 FY25
Q4 FY25
Q1 FY26
-5.8
-10.1
PAT (Rs. Cr.) / Margin (%)
20.1%
24.7
12.2%
14.3
0.6%
0.5
-13.5%
-14.6%
Q1 FY25
Q2 FY25
Q3 FY25
Q4 FY25
Q1 FY26
-9.7
-14.2
*Revenue consists of Other Operating Revenue **EBITDA is excl. Other Income
EPS (Rs.)
2.68
1.55
0.06
Q1 FY25
Q2 FY25
Q3 FY25
Q4 FY25
Q1 FY26
-1.05
-1.54
6
Consolidated Quarterly Financial Highlights – Q1 FY26
Particulars (Rs. Cr.)
Net Revenue Cost of Material Consumed Purchase of SIT Changes in Inventory Employee Expenses Other Expenses Total Expenditure EBITDA EBITDA Margin Other Income Depreciation Interest / Finance Cost
Add: Share of P/L of Associates & JV PBT Tax PAT PAT Margin% Basic EPS in Rs.
Q1 FY26 97.58 12.43 21.68 18.29 24.85 30.41 107.66 (10.08) (10.33%) 1.18 2.55 2.47
(0.14)
(14.06) 0.16 (14.22) (14.57%) (1.54)
Q1 FY25 122.99 23.52 16.74 1.01 21.60 30.95 93.82 29.18 23.72% 0.96 2.41 2.36
5.98
31.35 6.66 24.68 20.07% 2.68
Y-o-Y (%)
15%
15% (135%)
(145%)
(158%)
(157%)
Q4 FY25 71.70 18.98 16.30 (14.68) 25.45 31.45 77.49 (5.78) (8.07%) 1.55 2.53 2.45
(1.91)
(11.13) (1.46) (9.66) (13.48%) (1.05)
• Formulation Segment grew
35% Q-o-Q in Q1 FY26
• Revenue from Hospital and Trade businesses expanded 49% and 165% respectively on Q-o-Q basis in Q1 FY26
• API business continuous to recover with 52% Q-o-Q growth in Q1 FY26
7
Consolidated Financial Highlights – FY25
Particulars (Rs. Cr.)
Net Revenue
Cost of Material Consumed
Purchase of SIT
Changes in Inventory
Employee Expenses
Other Expenses
Total Expenditure
EBITDA
EBITDA Margin
Other Income
Depreciation
Interest / Finance Cost
Add: Share of P/L of Associates & JV
PBT
Tax
PAT
PAT Margin%
EPS in Rs.
FY25
405.51
76.31
73.67
(17.98)
96.38
128.10
356.46
49.05
12.10%
4.67
9.93
10.04
5.93
39.67
9.84
29.83
7.36%
3.24
FY24
381.76
84.67
53.61
(1.57)
82.41
111.13
330.26
51.51
13.49%
4.76
12.25
9.38
18.81
53.44
9.92
43.52
11.40%
4.73
Y-o-Y (%)
6.22%
7.94%
(4.77%)
(25.76%)
(31.46%)
(31.50%)
8
Consolidated Balance Sheet as on 31st Mar’25
Rs. Cr.
Shareholders Funds
Share Capital
Other Equity
Non Controlling interest
Non Current Liabilities
Long Term Borrowing
Lease Liabilities
LT Provisions
Deferred Tax Liability(net)
Current Liabilities
Short term Borrowings
Lease Liabilities
Trade Payables
Total outstanding dues of micro and small enterprises
Total outstanding dues of creditors other than micro and small enterprises
Other Financial Liabilities
Other Current Liabilities
Short term Provisions
Current Tax Liabilities (Net)
Total Equity & Liabilities
As on 31st Mar’25
As on 31st Mar’24
402.60
9.20
393.39
(0.0014)
29.31
18.61
0
1.86
8.83
156.12
64.37
0.00
3.31
48.12
31.53
1.13
1.80
5.85
377.67
9.20
368.46
0.00
35.77
26.77
0.00
1.60
7.39
152.98
69.02
0.00
3.08
44.21
27.40
0.89
0.96
7.42
588.03
566.42
Rs. Cr.
Non Current Assets
Plant, Property & Equipment
Capital Work In Progress
Right-of-use Assets
Intangible Assets
Investments
Financial Assets
Investments
Other Financial Assets
Deferred tax Assets (Net)
Other Non-Current Assets
Current Assets
Inventories
Financial Assets
Trade Receivables
Cash & Cash Equivalents
Bank balance other than above
Other Financial Assets
Other Current Assets
Total Assets
As on 31st Mar’25
As on 31st Mar’24
284.17
172.03
2.51
0.00
0.34
94.45
0.32
1.18
0.00
13.35
303.87
84.32
273.25
167.81
2.60
0.00
0.55
88.51
0.37
0.93
0.00
12.46
293.17
70.57
177.10
177.95
6.55
6.28
6.21
23.40
588.03
9.92
9.37
5.11
20.25
566.42
9
Company Overview
Snapshot of Company
Strategic focus To become Leader in Hospital Business in India with 4 growing divisions contributing 38.25% to revenue in FY24-25
3 State of art manufacturing facilities in India – 1 Formulations and 2 APIs (Synthetic + Biotech)
44+ Countries that we Export with Strong long- standing partnerships with global players for licensing (in & out).
Experienced professionals with proven capabilities – 7 PhDs, 234 Masters and 1,371 Others
Strong Balance Sheet Total Debt to Equity at 0.21 in FY24-25
Rs. 1,197 Cr Market Cap (As on 30th June 2025)
12.10% EBITDA Margin (FY24-25)
Rs. 29.83 Cr PAT (FY24-25)
11
Strong Business Model
01
Hospital Business is major growth driver
03
Hospital Business
▪ Critical Care Division ▪ Intensive Care Division ▪ Institution Business ▪ Exports
API Business
n
▪ API Legacy Business ▪ New Product pipeline
supports hospital strategy and standalone global opportunities
n
02
Trade Business
n
▪ Pharma Division ▪ Ortho Division ▪ Gynecology Division ▪ Strategy for growing through key brand focus in each division
Businesswise Revenue – Q1 FY26
API, Co. Mkt & Others 29%
Trade 26%
Hospital 45%
Businesswise Revenue – FY24-25
Hospital 38%
API, Co. Mkt & Others 42%
Trade 20%
Critical Care and Intensive Care teams contribute to building Hospital Business with new launches and increased hospitals/doctor’s coverage
12
Vertically Integrated State of Art Manufacturing Capabilities
Particulars
Location
Haridwar
Hyderabad
Vapi
Themis Medicare Ltd.
Artemis Biotech (Division of Themis Medicare Ltd.)
Themis Medicare Ltd.
Segment
Formulations
Synthetic APIs
Synthetic APIs
Capacity (per annum)
Tablets (Nos.) - 520 mn Ointment (No. of Tubes) - 9 mn Ampoules (No. of Amp) - 36 mn Vials (No. of Vials) - 12 mn Pre-filled Syringes (Nos.)- 6 mn
120 MT
Regulatory Approvals
EU GMP Certificate – Tablets & Gels
EU GMP
191 MT
GMP
Photos
13
Strong Research and Development Capabilities
Continued Investment in R&D (Rs. Cr.)
Business
API
Formulations
13.64
14.25
13.69
13.21
8.50
R&D
Analytical Lab Development
15
7
4
5
Product in a year with documentation
5 – 8
20-24
FY20-21
FY21-22
FY22-23
FY23-24
FY24-25
Products in work rolling
3 – 5
31
14
Way Ahead
Hospital Business Opportunity
n
Why Hospital Business Segment? ▪ Growing market - Themis has strong foot in door through Critical
Care
▪ Market Highly Fragmented unlike West where 3-4 players control
90% market share
▪ Opportunities to grow segments within HB
High Entry Barriers ▪ ▪
Large Product Portfolio needed to service this segment Takes time to build relationship and reputation with key accounts
Opportunities Ahead ▪ Focus on achieving Leadership position in India with Corporate Hospitals and Nursing Homes ▪ With Expertise in Development of Complex Injectables - Company well placed to reap benefits
16
Our Aspirations
Strategy
▪ Focus on Hospital business ▪ APIs to be developed - in-house consumption and commercial production
Growth
▪ CAGR of 35% over next 3 years ▪ Maintain EBIDTA of over 25%
Vision & Position
▪ Provide hospitals and health systems ‘The Best Experience Leader business model” to ensure customer satisfaction
▪ Leadership in Anesthesia and Critical Care
New Target Markets
▪ Expansion in new RoW Markets in Phase I (0 to 3 years
- CIS, Latin America, GCC)
▪ Enter Regulated Markets in Phase II within 3 to 5 years
– EU, USA
17
Thank You
It takes one word to change
the world “POSSIBILITY”
For further information, please contact:
Mr. Pradeep Chandan
Themis Medicare Ltd Email: pradeep.chandan@themismedicare.com Website: www.themismedicare.com
Mr. Amit Sharma / Mr. Rahul Trivedi Tel: +91 9867726686 / 9833541841
Adfactors PR Pvt Ltd Email: amit.sharma@adfactorspr.com / rahul.Trivedi@adfactorspr.com Website : www.adfactorspr.com
18